1. Is Glenmark Life Sciences Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Glenmark Life Sciences Ltd is a good quality company.
2. Is Glenmark Life Sciences Ltd undervalued or overvalued?
The key valuation ratios of Glenmark Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Glenmark Life Sciences Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Glenmark Life Sciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||0%||0%||0%||0%||0%||31%||463.8%||134.6%||72%||30.9%||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||NA||NA||NA||NA||NA||3,54,468%||73.4%||22.6%||12.6%||-|
|Adj EPS ⓘ||0||0||0||0||0||-7.9||18.6||28.4||32.9||33.8||34.1|
|YoY Gr. Rt. %||-||NA||NA||NA||NA||NA||NA||52.5%||15.8%||2.7%||-|
|BVPS (₹) ⓘ||0||0||0||0||0||-25.4||8.2||37.3||69.8||167.4||174.9|
|Adj Net Profit ⓘ||0||0||0||0||0||-0.4||201||306||354||414||418|
|Cash Flow from Ops. ⓘ||0||0||0||0||0||-0.5||10.4||195||388||598||-|
|Debt/CF from Ops. ⓘ||0||0||0||0||0||0||0||0||0||0||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||NA||NA||22%||2.7%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||0||0||0||0||0||31||462.9||125||61.4||29.5||19.9|
|Op. Profit Mgn % ⓘ||0||0||0||0||0||-5.2||28.7||30.8||31.6||29.1||28.4|
|Net Profit Mgn % ⓘ||0||0||0||0||0||-175||22.7||19.9||18.8||19.5||20.6|
|Debt to Equity ⓘ||0||0||0||0||0||0||0||0||0||0||0|
|Working Cap Days ⓘ||0||0||0||0||0||0||193||248||258||271||333|
|Cash Conv. Cycle ⓘ||0||0||0||0||0||0||123||160||151||134||245|
Sales growth is growing at healthy rate in last 3 years 33.80%
Net Profit is growing at healthy rate in last 3 years 21.96%
Return on Equity has declined versus last 3 years average to 19.90%
Sales growth is not so good in last 4 quarters at -0.38%
|TTM EPS (₹)||34.1||-|
|TTM Sales (₹ Cr.)||2,036||-|
|BVPS (₹.) ⓘ||174.9||-|
|Reserves (₹ Cr.) ⓘ||2,118||-|
|From the Market|
|52 Week Low / High (₹)||375.00 / 637.70|
|All Time Low / High (₹)||375.00 / 799.95|
|Market Cap (₹ Cr.)||5,302|
|Equity (₹ Cr.)||24.5|
|Face Value (₹)||2|
|Industry PE ⓘ||37.8|
Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflects its capability to branch into other high value products. It has strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). It are also increasingly providing contract development and manufacturing operations (CDMO) services to a range of multinational and specialty pharmaceutical companies. It is a research and development (R&D)-driven API manufacturer, focused on undertaking dedicated R&D in its existing products and in areas where there is growth potential in the future. Maintaining high standards of process innovation and quality in its R&D and manufacturing operations is critical to its brand and maintenance of long-term relationships with its customers.
The company currently operates four multi-purpose manufacturing facilities which are situated on leasehold properties located at Ankleshwar and Dahej in the state of Gujarat, India, and Mohol and Kurkumbh in the state of Maharashtra, India with an aggregate annual total installed capacity of 726.6 KL as of March 31, 2021. Its R&D laboratories focus on new product development and complex molecules, cost improvement programs, process improvements and oncology product development. To assist it with its R&D initiatives, it has established dedicated teams for new product development, complex products, oncology product development, technology transfer, life cycle management and project management.’ It has a professional and experienced management team. Its management team has demonstrated the ability to successfully build and integrate its businesses with various operating activities through their cumulative years of work experience. In particular, they have led the process through which it has created value through organic growth, built brand recognition and loyalty and identified new business opportunities.
Business area of the company
The company is in the business of making high-quality drugs by unlocking the possibilities of science.
Awards, accreditations and recognitions
Major events and milestones